Health Canada gave the green light on Tuesday to the initial generic version of Novo Nordisk’s Ozempic drug. The approval was granted for a generic semaglutide injection by Dr. Reddy’s Laboratories, an Indian pharmaceutical company, following a comprehensive evaluation of evidence. Health Canada confirmed that the generic drug met the required safety, efficacy, and quality standards.
Dr. Kaberi Dasgupta, a physician-scientist and McGill University professor of medicine, expressed enthusiasm for the approval, emphasizing the potential cost reduction that generic medications could bring due to the high prices of existing options.
The approval of a generic version of the drug has been eagerly awaited by patients and healthcare providers, particularly for managing Type 2 diabetes and aiding in weight loss. An estimated three million Canadian adults are currently using GLP-1 drugs like Ozempic, with many more interested in trying them but facing cost barriers.
Aside from its established benefits in diabetes and weight management, researchers are exploring the potential of Ozempic in addressing addictions to substances like alcohol and opioids.
Health Canada specified that the generic semaglutide is intended for once-weekly treatment of adult patients with Type 2 diabetes to regulate blood sugar levels. The department highlighted that the generic drugs are pharmaceutically equivalent to the brand-name product.
Novo Nordisk’s exclusive rights to semaglutide, the key ingredient in Ozempic and Wegovy, expired earlier this year, opening the door for generic competition. The availability of generic alternatives is expected to significantly reduce costs for patients and the healthcare system.
Experts anticipate substantial cost savings with the introduction of multiple generic versions. Health Canada mentioned that generic medications typically cost 45 to 90 percent less than branded counterparts. As more generics enter the market, prices could potentially drop to around $100 or lower, offering more affordable options for patients.
While the approval of generics is a positive development, healthcare professionals like Dasgupta emphasize the importance of using semaglutide under proper medical supervision, combined with a healthy lifestyle. Public health messaging is crucial to ensure the safe and appropriate use of these medications and to avoid potential risks associated with misuse.
The exact availability date for Dr. Reddy’s generics is currently unknown, as Health Canada is reviewing several other generic submissions from different companies. The department will continue to monitor the safety and effectiveness of all generic semaglutides in the market.
